FI4181920T3 - Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon - Google Patents

Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon

Info

Publication number
FI4181920T3
FI4181920T3 FIEP21749550.6T FI21749550T FI4181920T3 FI 4181920 T3 FI4181920 T3 FI 4181920T3 FI 21749550 T FI21749550 T FI 21749550T FI 4181920 T3 FI4181920 T3 FI 4181920T3
Authority
FI
Finland
Prior art keywords
inhibitor
kat6
pharmaceutically acceptable
acceptable salt
breast cancer
Prior art date
Application number
FIEP21749550.6T
Other languages
English (en)
Inventor
Paul Anthony Stupple
Anthony Mazurek
Kim Timothy Arndt
Lei Chen
Maximillian Todd Follettie
David Scott Fruhling
Pei-Pei Kung
Wenyan Zhong
Philip Michael Tedeschi
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Application granted granted Critical
Publication of FI4181920T3 publication Critical patent/FI4181920T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

PATENTTIVAATIMUKSET
1. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi menetelmässä syövän hoitamiseksi, jossa mainittu menetelmä käsittää mainitun lysiiniase- tyylitransferaasi 6:n (KAT6) estäjän määrän ja a) sykliiniriippuvaisen kinaasi 4:n (CDK4) es- täjän määrän; tai b) antiestrogeenin määrän; tai c) CDK4-estäjän määrän ja antiestrogeenin mää- rän antamisen sitä tarvitsevalle potilaalle; jossa määrät yhdessä ovat terapeuttisesti te- hokkaita syövän hoidossa; jossa syöpä on rintasvyöpä; jossa KAT6-estäjä on 2-metoksi-N-{4-metoksi- 6- [ (1H-pyratsol-1-vyli)metyyli]-1,2-bentsoksatsol-3- yylijbentseeni-1-sulfonamidi tai sen farmaseuttisesti hyväksyttävä suola; jossa antiestrogeeni on ful- vestrantti; ja jossa CDK4-estäjä on joko 1,5-anhydro-3-({5- kloori-4-[4-fluori-2-(2-hydroksipropan-2-yyli)-1-(pro- pan-2-yyli)-1H-bentsimidatsol-6-yylilpyrimidin-2- yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen far- maseuttisesti hyväksyttävä suola tai palbosiklibi tai sen farmaseuttisesti hyväksyttävä suola.
2. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi menetelmässä, jolla voitetaan klii- ninen resistenssi endokriinistä hoitoa vastaan, jossa mainittu menetelmä käsittää mainitun KAT6-estäjän ja CDK4-estäjän määrän antamisen sitä tarvitsevalle poti- laalle, jossa määrät yhdessä ovat terapeuttisesti te- hokkaita voittamaan kliinisen resistenssin endokrii- nistä hoitoa vastaan; jossa endokriinistä hoitoa käytetään rinta- syövän hoidossa;
jossa KAT6-estäjä on 2-metoksi-N-{4-metoksi- 6- [ (1H-pyratsol-1-vyli)metyyli]-1,2-bentsoksatsol-3- yylijbentseeni-1-sulfonamidi tai sen farmaseuttisesti hyväksyttävä suola; ja jossa CDK4-inhibiittori on joko 1,5-anhydro- 3- ( (5-kloori-4-[4-fluori-2-(2-hydroksipropan-2-vyvyli)- 1- (propan-2-yyli)-1H-bentsimidatsol-6-yylilpyrimidin- 2-yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen farmaseuttisesti hyväksyttävä suola tai palbosiklibi tai sen farmaseuttisesti hyväksyttävä suola.
3. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi patenttivaatimuksen 1 tai patentti- vaatimuksen 2 mukaisesti, jossa CDK4-estäjä on 1,5- anhydro-3- ( (5-kloori-4-[4-fluori-2-(2-hydroksipropan- 2-yyli)-1-(propan-2-yyli)-1H-bentsimidatsol-6-yylilpy- rimidin-2-yylijamino)-2,3-dideoksi-D-treo-pentitoli tai sen farmaseuttisesti hyväksyttävä suola.
4. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi patenttivaatimuksen 1 tai patentti- vaatimuksen 2 mukaisesti, jossa CDK4-estäjä on palbosi- klibi tai sen farmaseuttisesti hyväksyttävä suola.
5. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1-4 mu- kaisesti, jossa potilas on ihminen.
6. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1 tai 2 mukaisesti, jossa rintasyöpä on paikallisesti edennyt tai metastasoitunut estrogeenireseptoripositiivinen (ER+) rintasyöpä.
7. Lysiiniasetyylitransferaasi 6:n (KAT6) es- täjä käytettäväksi jonkin patenttivaatimuksista 1 tai 2 mukaisesti, jossa rintasyöpä on paikallisesti edennyt tai metastasoitunut estrogeenireseptoripositiivinen (ER+) ja ihmisen epidermaalisen kasvutekijän reseptori 2 -negatiivinen (HER2-) rintasvyöpä.
FIEP21749550.6T 2020-07-15 2021-07-15 Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon FI4181920T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052215P 2020-07-15 2020-07-15
US202163211044P 2021-06-16 2021-06-16
PCT/EP2021/069787 WO2022013369A1 (en) 2020-07-15 2021-07-15 Kat6 inhibitor methods and combinations for cancer treatment

Publications (1)

Publication Number Publication Date
FI4181920T3 true FI4181920T3 (fi) 2025-11-20

Family

ID=77179980

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21749550.6T FI4181920T3 (fi) 2020-07-15 2021-07-15 Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon

Country Status (17)

Country Link
EP (2) EP4181920B1 (fi)
JP (1) JP2022019654A (fi)
KR (1) KR102976842B1 (fi)
AU (2) AU2021308406A1 (fi)
BR (1) BR112023000687A2 (fi)
CA (1) CA3189410A1 (fi)
DK (1) DK4181920T3 (fi)
ES (1) ES3050760T3 (fi)
FI (1) FI4181920T3 (fi)
HU (1) HUE073220T2 (fi)
IL (1) IL299871A (fi)
MX (1) MX2023000735A (fi)
PT (1) PT4181920T (fi)
SI (1) SI4181920T1 (fi)
TW (1) TW202216131A (fi)
WO (1) WO2022013369A1 (fi)
ZA (1) ZA202300875B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240140947A1 (en) * 2022-10-18 2024-05-02 Pfizer Inc. Compound for the treatment of cancer

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072394A (zh) 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
US20240400545A1 (en) * 2021-07-05 2024-12-05 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
MX2024005839A (es) 2021-11-16 2024-06-26 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
AU2022400308B2 (en) * 2021-12-02 2026-02-12 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
CN116621859B (zh) * 2022-02-18 2026-06-12 山东轩竹医药科技有限公司 三并环类kat6抑制剂
US12187732B2 (en) 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのkat6阻害剤を含む投与レジメン
EP4692094A1 (en) * 2023-03-27 2026-02-11 Beijing Konruns Pharmaceutical Co., Ltd. Sulfonamide compound, pharmaceutical composition thereof and use thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
AR132470A1 (es) * 2023-04-19 2025-07-02 Insilico Medicine Ip Ltd Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
AU2024325442A1 (en) 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
CN117448454B (zh) * 2023-10-30 2025-09-30 赣南医科大学 Kat6a在制备结直肠癌肝转移诊断试剂盒中的应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide
WO2026060321A1 (en) * 2024-09-13 2026-03-19 Olema Pharmaceuticals, Inc. Kat6 degrader compounds and method thereof
WO2026133163A1 (en) 2024-12-19 2026-06-25 Pfizer Inc. Film coated solid dosage forms for management of dysgeusia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
GB201510019D0 (en) * 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EP3850381A2 (en) 2018-09-10 2021-07-21 3M Innovative Properties Company Electrical power cable monitoring device including partial discharge sensor
CN114072394A (zh) * 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
SI4299135T1 (sl) * 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240140947A1 (en) * 2022-10-18 2024-05-02 Pfizer Inc. Compound for the treatment of cancer

Also Published As

Publication number Publication date
KR102976842B1 (ko) 2026-06-15
CN116113407A (zh) 2023-05-12
JP2022019654A (ja) 2022-01-27
IL299871A (en) 2023-03-01
TW202216131A (zh) 2022-05-01
DK4181920T3 (da) 2025-09-29
HUE073220T2 (hu) 2026-01-28
WO2022013369A1 (en) 2022-01-20
BR112023000687A2 (pt) 2023-02-07
EP4667055A3 (en) 2026-02-25
KR20230058614A (ko) 2023-05-03
ZA202300875B (en) 2023-09-27
SI4181920T1 (sl) 2026-01-30
EP4181920A1 (en) 2023-05-24
EP4181920B1 (en) 2025-09-10
MX2023000735A (es) 2023-02-13
AU2025200238A1 (en) 2025-01-30
ES3050760T3 (en) 2025-12-22
EP4667055A2 (en) 2025-12-24
AU2021308406A1 (en) 2023-02-23
PT4181920T (pt) 2025-11-04
CA3189410A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
IL299871A (en) Methods and combinations of KAT6 inhibitors for the treatment of cancer
RU2016129953A (ru) Фармацевтические комбинации
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
ATE300262T1 (de) Allzweck -medikament und -wärmebehandlungssystem
WO2010034019A4 (en) Transdermal drug delivery using an osmolyte and vasoactive agent
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
DE50209721D1 (de) Screeningverfahren mit pim1-kinase oder pim3-kinase
MX2025004433A (es) Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer
BRPI0517976A (pt) métodos de tratamento
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
CN104083200B (zh) 一种骨科固定装置
MX2009012060A (es) Metodo de acupuntura y la aguja para llevar a cabo dicho método.
EP1591450A4 (en) CONJUGATE FOR RETENTION IN THE BLOOD AND CANCER-SPECIFIC ACTIVE EXTRACTION
CN203898412U (zh) 一种骨科固定装置
DE60120917D1 (de) Kombinationspräparat zur krebstherapie
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
FI3448430T3 (fi) Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi
CN211325439U (zh) 一种超声引导下人体软组织压痛点针药合一、标本兼治系统
Gupta Transdermal drug delivery system
ATE454397T1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
RU2007111754A (ru) Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
Reddy et al. Review on transdermal drug delivery system
CN309614980S (zh) 电极敷贴
Lakhmani et al. Drug delivery through nails: An overview